Abstract |
The intensity of adjuvant radiotherapy for stage I seminoma could be reduced substantially in recent years, achieving cure with low side effects and a low probability of late complications. Today a dose of 20 Gy is applied to the para-aortic lymphatics. Valuable treatment alternatives to radiotherapy have emerged: surveillance strategy allows 80% of patients to avoid further treatment. However, the remaining 20% will be exposed to potentially more intensive salvage therapy. Adjuvant carboplatinum chemotherapy offers similar disease-free survival to adjuvant radiotherapy. Long-term experience with late toxicity is not available. In seminoma CS IIA/B curative irradiation remains the standard treatment. Brain metastases of testicular germ cell tumors are treated with a combination of chemotherapy and cranial irradiation. In intratubular germ cell neoplasia ( TIN), radiotherapy with 20 Gy will safely eliminate all TIN loci, but will destroy potential residual fertility.
|
Authors | R Souchon, J Classen, H Schmidberger |
Journal | Der Urologe. Ausg. A
(Urologe A)
Vol. 43
Issue 12
Pg. 1500-6
(Dec 2004)
ISSN: 0340-2592 [Print] Germany |
Vernacular Title | EbM-basierte Indikationen zur Radiotherapie von testikulären Keimzellmalignomen. |
PMID | 15502911
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Brain Neoplasms
(drug therapy, radiotherapy, secondary)
- Clinical Trials as Topic
- Evidence-Based Medicine
- Humans
- Male
- Neoplasms, Germ Cell and Embryonal
(drug therapy, radiotherapy, secondary)
- Practice Guidelines as Topic
- Practice Patterns, Physicians'
- Radiotherapy
(methods)
- Radiotherapy, Adjuvant
(methods)
- Risk Assessment
(methods)
- Risk Factors
- Testicular Neoplasms
(drug therapy, radiotherapy)
- Treatment Outcome
|